Patent · US Active

Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis

US10994010B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignees

Inventors

Andreas Zirlik · Glückstadt, DE
Dennis Wolf · Westlake, US
Karlheinz Peter · Molfsee, DE

Key dates

Filing date	Dec 4, 2019
Grant date	May 4, 2021
Priority date	—
Expiry date	Dec 4, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.